ClinicalTrials.gg
Not yet recruitingNCT07680907LuCaRTEUpdated Aug 28, 2026

A Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm)

An observational study in Carcinoma, Non-Small-Cell Lung, sponsored by Janssen-Cilag Farmaceutica Ltda.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Janssen-Cilag Farmaceutica Ltda. (part of Johnson & Johnson) · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson — 7 open to participants now, 18 under way, 4 of them phase 3. Carcinoma, Non-Small-Cell Lung · Johnson & Johnson.

Started
2026
with 2 others
Observational
7 of 36
2 open now
Primary completion
2026-11
later than 5 of 17 live
Registered
36th of 36
by date

Among the 36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson, this one is one of 3 that started in 2026, is one of 7 observational ones, reaches primary completion later than 5 of the 17 other live ones, and was the 36th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson, or all of them as a file.
02

Study summary

This study aims to better understand people who have advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR mutation. NSCLC is an advanced stage cancer of the lung, occurring due to mutations (changes) in the EGFR gene. The study will assess the participant demographic background (that is age, gender etc.), the treatments they receive, how well those treatments work, and their health outcomes.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult participants (aged greater than or equal to [>=] 18 years) with a histologically or cytologically confirmed diagnosis of NSCLC, unresectable stage IIIB/C or IV at diagnosis, and a documented EGFR mutation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of advanced or unresectable non-small cell lung cancerNSCLC (TNM stages IIIB-IV), and a documented EGFR mutation, between 01 July 2018 and 31 March 2022
  • Diagnosed and treated at one of the participating study centers within the defined study period

Exclusion criteria

Exclusion criteria:

  • Participants who received any systemic cancer treatment outside the participating treatment centers
  • Participants diagnosed with any other within the 5 years prior to or during the study period, with the exception of cutaneous basal cell carcinoma or squamous cell carcinoma
  • Participants enrolled in clinical trials during the study period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • Unresectable Epidermal Growth Factor Receptor Mutated (EGFRm) NSCLC

    Participants with a histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC), unresectable stage IIIB/C or IV at diagnosis, and a documented EGFR mutation will be included in this cohort. The existing secondary data from electronic health records (EHR) of these participants from approximately five selected Portuguese healthcare sites will be processed. Each participant will be followed up from index date (date on which participant is included in study) up to 31 March 2026 or at censoring, No intervention will be provided as a part of this study.

06

What researchers measure

Primary outcomes

  1. Sociodemographic Characteristics: Age

    Age in years of the participants will be reported.

    Time frame: Baseline

  2. Sociodemographic Characteristics: Sex

    Sex (male, female) of the participants will be reported.

    Time frame: Baseline

  3. Sociodemographic Characteristics: Weight

    Weight (in kilograms \[kg\]) of the participants will be reported.

    Time frame: Baseline

  4. Sociodemographic Characteristics: Smoking Status

    Participants smoking status that is current or former smoker will be reported.

    Time frame: Baseline

  5. Sociodemographic Characteristics: Eastern Cooperative Oncology Group (ECOG) Performance Status

    ECOG performance status of the participants will be reported.

    Time frame: Baseline

  6. Sociodemographic Characteristics: Disease Histopathology

    Number of participants based on disease histopathology will be reported.

    Time frame: Baseline

  7. Sociodemographic Characteristics: Type of Mutation

    Number of participants based on type of mutation will be reported.

    Time frame: Baseline

  8. Sociodemographic Characteristics: Disease Stage

    Number of participants based on the stage of disease will be reported.

    Time frame: Baseline

  9. Sociodemographic Characteristics: Cancer Metastasis

    Number of participants based on cancer metastasis will be reported.

    Time frame: Baseline

  10. EGFR Mutation Prevalence

    Number of participants with EGFR mutations will be reported.

    Time frame: Up to approximately 7 years 9 months

  11. Percentage of Participants by Type of Mutation of EGFR

    Percentage of participants by type of mutation of EGFR will be reported.

    Time frame: Up to approximately 7 years 9 months

Secondary outcomes

  1. Frequency of EGFR Mutations

    Frequency of EGFR mutations will be reported.

    Time frame: Up to approximately 7 years 9 months

  2. Number of Participants by Treatment Options

    Participants with different treatment options such as targeted therapy, chemotherapy, immunotherapy, surgery, radiotherapy stratified by type of mutation will be reported.

    Time frame: Up to approximately 7 years 9 months

  3. Real-World Overall Survival (RW-OS)

    RW-OS is defined as time elapsed between index date and date of death from any cause.

    Time frame: Up to approximately 7 years 9 months

  4. Real-World Progression-Free Survival (RW-PFS)

    RW-PFS is defined as the time elapsed between the start of a new line of treatment to the date of documented disease progression or death from any cause, whichever occurs first.

    Time frame: Up to approximately 7 years 9 months

  5. RW-PFS from First Line of Treatment (RW-PFS 2)

    RW-PFS 2 is defined as the time elapsed between the start of a first line of treatment to the date of documented second disease progression or death from any cause, whichever occurs first.

    Time frame: Up to approximately 7 years 9 months

  6. Real-World Time on Treatment (RW-TOT)

    RW-TOT is defined as the time elapsed between the start date of a line of treatment to the date of treatment discontinuation for any reason.

    Time frame: Up to approximately 7 years 9 months

  7. Real-World Time to Next Treatment (RW-TTNT)

    RW-TTNT is defined as the time elapsed between the start of a given line of treatment to the initiation of the subsequent line of systemic therapy.

    Time frame: Up to approximately 7 years 9 months

  8. Real-World Overall Response Rate (RW-ORR)

    RW-ORR is defined as the percentage of participants whose cancer show partial response or complete response of all target lesions following a specific line of treatment.

    Time frame: Up to approximately 7 years 9 months

  9. Number of Appointments

    Number of appointments related to NSCLC by line of treatment such as oncology, pulmonology, primary care, radio-oncology, thoracic surgery, nursing, psychology, nutrition, physiotherapy will be reported.

    Time frame: Up to approximately 7 years 9 months

  10. Number of Participants Receiving Complementary Diagnostic and Therapeutic Procedures

    Number of participants receiving complementary diagnostic and therapeutic procedures and type of complementary diagnostic and therapeutic procedures received (for example, imaging, laboratory tests, biopsies, radiotherapy sessions, surgery, medication) will be reported.

    Time frame: Up to approximately 7 years 9 months

  11. Number Participants with Emergency Room Visits Related to NSCLC

    Number of participants with emergency room visits related to NSCLC will be reported.

    Time frame: Up to approximately 7 years 9 months

  12. Percentage of Participants Hospitalized

    Percentage of participants with at least one hospitalization will be reported.

    Time frame: Up to approximately 7 years 9 months

  13. Number of Hospitalizations

    Total number of hospitalizations for the participants will be reported.

    Time frame: Up to approximately 7 years 9 months

  14. Median Length of Stay

    Median length of stay in days per hospitalization will be reported.

    Time frame: Up to approximately 7 years 9 months

  15. Net Costing

    The net cost of different treatment practices per participants will be reported.

    Time frame: Up to approximately 7 years 9 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Data sharing details ↗ · innovativemedicine.jnj.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Nov 2026, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Jul 2, 2026
StartEst.
Oct 31, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07680907
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Oct 31, 2026 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 28, 2026

Study contacts

Study Contact
Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Janssen-Cilag Farmaceutica, Lda. Clinical Trial
study director · Janssen-Cilag Farmaceutica, Lda.

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion